

# 1 Dopaminergic-related Anatomical Pattern of Dorsal Striatum in Schizophrenia

2 Chao Xie<sup>1,2</sup>, Shitong Xiang<sup>1,2</sup>, Yueyuan Zheng<sup>3</sup>, Chun Shen<sup>1,2</sup>, Xuerui Peng<sup>4</sup>, Yuzhu Li<sup>1,2</sup>, Wei Cheng<sup>1,2</sup>, Xiao  
3 Chang<sup>1,2</sup>, Jingliang Cheng<sup>5</sup>, Long-Biao Cui<sup>6</sup>, Chu-Chung Huang<sup>7,8</sup>, Nanyu Kuang<sup>1,2</sup>, Chunbo Li<sup>9</sup>, Ching-Po  
4 Lin<sup>10</sup>, Cheng Luo<sup>11,12,13</sup>, Yingying Tang<sup>9</sup>, Jijun Wang<sup>9</sup>, Xinran Wu<sup>1,2</sup>, Dezhong Yao<sup>11,12,13</sup>, Jie Zhang<sup>1,2</sup>,  
5 Tianhong Zhang<sup>9</sup>, Andreas Heinz<sup>14</sup>, Trevor W. Robbins<sup>1,15</sup>, Oliver D. Howes<sup>16,17,18</sup>, Gunter Schumann<sup>1,19,20,21</sup>,  
6 Tianye Jia<sup>1,2,22</sup>, Jianfeng Feng<sup>1,2,23,24,25,26,27</sup>

7  
8 <sup>1</sup>Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China

9 <sup>2</sup>Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry  
10 of Education, China

11 <sup>3</sup>Department of Psychology, University of Hong Kong, Hong Kong, China

12 <sup>4</sup>Faculty of Psychology, Chair of Lifespan Developmental Neuroscience, Technische Universität Dresden,  
13 Dresden, Germany

14 <sup>5</sup>Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

15 <sup>6</sup>Department of Clinical Psychology, Fourth Military Medical University, Xian, China

16 <sup>7</sup>Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), Affiliated Mental Health  
17 Center (ECNU), School of Psychology and Cognitive Science, East China Normal University, Shanghai,  
18 China

19 <sup>8</sup>Shanghai Changing Mental Health Center, Shanghai, PR China. <sup>15</sup>Department of Psychiatry, Taipei Veterans  
20 General Hospital, Taipei, Taiwan

21 <sup>9</sup>Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong  
22 University School of Medicine, Shanghai, China

23 <sup>10</sup>Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei, Taiwan

24 <sup>11</sup>The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, School of  
25 Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China

26 <sup>12</sup>High-Field Magnetic Resonance Brain Imaging Key Laboratory of Sichuan Province, Center for Information  
27 in Medicine, University of Electronic Science and Technology of China, Chengdu, China

28 <sup>13</sup>Research Unit of NeuroInformation (2019RU035), Chinese Academy of Medical Sciences, Chengdu, China

29 <sup>14</sup>Department of Psychiatry and Psychotherapy, Charité–Universitätsmedizin Berlin, corporate member of  
30 Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

31 <sup>15</sup>University of Cambridge, Cambridge, UK

32 <sup>16</sup>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

33 <sup>17</sup>Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK

34 <sup>18</sup>South London and Maudsley NHS Foundation Trust, London, UK

35 <sup>19</sup>PONS-Research Group, Charité Mental Health, Department of Psychiatry and Psychotherapy, Campus  
36 Charité Mitte, Berlin, Germany

37 <sup>20</sup>Department of Sports and Health Sciences, University of Potsdam, Potsdam, Germany.

38 <sup>21</sup>PONS Centre, Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University,

39 Shanghai, China

40 <sup>22</sup>SGDP Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5

41 8AF, UK

42 <sup>23</sup>Fudan ISTBI-ZJNU Algorithm Centre for Brain-Inspired Intelligence, Zhejiang Normal University, Jinhua,

43 China

44 <sup>24</sup>MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China

45 <sup>25</sup>Zhangjiang Fudan International Innovation Center, Shanghai, China

46 <sup>26</sup>School of Data Science, Fudan University, Shanghai, China

47 <sup>27</sup>Department of Computer Science, University of Warwick, Coventry, UK

48

49 \*Correspondece: [tianyejia@fudan.edu.cn](mailto:tianyejia@fudan.edu.cn); [jianfeng64@gmail.com](mailto:jianfeng64@gmail.com)

50 Drs. Tianye Jia, Oliver D. Howes, Gunter Schumann and Jianfeng Feng contributed equally to this work

51

52 **Abstract**

53       Striatal dopaminergic overactivity was hypothesized as the core pathophysiology of schizophrenia.  
54       However, morphological alterations of striatum in schizophrenia remains exclusive, largely because brain  
55       regional heterogeneity limited traditional group-mean based approach. Leveraging third-party brain maps of  
56       neurotransmitter and cognition behaviours, we developed a pattern-based representation feature score (ReFS)  
57       to investigate structural spatial pattern variation in schizophrenia. Structural ReFS of subcortical regions,  
58       particularly the striatum, were linked to schizophrenia diagnosis, symptom severity, and genetic susceptibility.  
59       Dopaminergic-ReFS of striatum was increased in schizophrenia patients and reliably reproduced across 13  
60       datasets. The pattern-based ReFS effectively captured the shared genetic pathways underlying both  
61       schizophrenia and striatum. The results provide convergent, multimodal suggest the central role of striatal  
62       spatial patterns in schizophrenia psychopathologies and and open new avenues to develop individualized  
63       treatments for psychotic disorders.

64 **Introduction**

65       Schizophrenia and related psychotic disorders are major contributors to worldwide disease burden, which is  
66       partly due to the lack of efficacy of antipsychotic drugs for many patients, as well as significant side effects caused  
67       by the medication (1). Both shortcomings are likely related to an insufficient understanding of the neurobiological  
68       mechanisms underlying the disorder. Thus there is a need to improve understanding of the pathophysiology of  
69       schizophrenia to help develop better treatments (2). Several lines of in vivo imaging evidence suggest that  
70       increased striatal dopamine synthesis and release capacity underlie psychotic symptoms (3), including across  
71       disorders (4). While these studies identify the striatum as a key brain region in the etiology of psychotic disorders, a  
72       comprehensive understanding of striatal abnormalities beyond increased dopamine release remains elusive (5). In  
73       particular, the evidence for striatal volume alterations in schizophrenia is inconsistent (6, 7).

74       One reason for this inconsistency could be because group mean-based gray matter volume of brain regions has  
75       commonly been used to examine the structural differences in schizophrenia, based on the implicit assumption that  
76       there is homogeneity in the measure between groups within each region of interest. However, mounting evidence  
77       suggests there is greater heterogeneity among structural measures in schizophrenia patients compared to controls  
78       (8). Moreover, other evidence shows that levels and activity of neurotransmitter systems varied spatial distribution  
79       within brain regions, and that people with schizophrenia show differences in this which are missed by regional  
80       comparisons (9, 10). These findings indicate that the region-based approaches to analysis brain data miss intricate,  
81       high-dimensional spatial information within the brain that are relevant to understanding mental disorders such as

82 schizophrenia(11, 12).

83 To address this, we aimed to develop and test a reference-based method that analysed the pattern of variation  
84 in brain structural data (**Fig S1**). We decomposed the complex spatial information of brain structure in MRI scans  
85 by transforming region-level spatial pattern of grey matter volume into a multidimensional representational space  
86 that was constructed using a specific third-party functional reference map (**Fig. 1a**). Specifically, for each brain  
87 region, we normalized individual-level grey matter volume (GMV) and group-level functional reference maps,  
88 followed by calculating the paired-wise spatial similarity for each individual. This process generates  
89 representational feature scores (ReFS) of latent brain functions for each brain region. We then tested and  
90 demonstrated that the spatial reference was highly reliable across datasets, and the structural ReFS has excellent  
91 reproducibility across scanner types, sequences, and time points, as well as a high sensitivity to individual  
92 differences (**Table S1, Fig. 1b and Fig S3-6**). Next, we discovered that structural ReFS of subcortical regions,  
93 particularly the striatum, were linked to schizophrenia diagnosis, symptom severity, and genetic susceptibility (**Fig**  
94 **S2**). Finally, we revealed that it was the reference-based ReFS, rather than mean-based volume based on region of  
95 interest analysis, that effectively captured the shared genetic pathways underlying both schizophrenia and brain  
96 structure.

97

## 98 **Results**

### 99 *Altered representation feature scores (ReFS) of striatum structure in schizophrenia.*

100 As neurotransmitter receptors are central to the propagation of signals in the human brain, we first estimated  
101 brain structural representational feature scores based on neurotransmitter maps derived from positron emission  
102 tomography (termed as PET-ReFS, **Fig S7**). We found that in a large-scale multisite schizophrenia dataset (1,229  
103 SCZ participants, 1,237 HC participants, **Table S2**), the Schizophrenia group showed significantly higher  
104 dopamine-ReFS of striatal regions, including posterior putamen (pPUT), anterior putamen (aPUT) and core  
105 Nucleus Accumbens (coreNAC) (**Fig. 1c, Table S3**). Besides, we also found that schizophrenia patients showed  
106 lower gamma-aminobutyric acid (GABAa)-ReFS in aPUT and pPUT (**Fig. 1c, Table S3**). After statistically  
107 accounting for the influence of one another, the results of GABAa-ReFS and dopamine-ReFS remained significant  
108 (**Table S3**), suggesting that the two neurotransmitters have unique contributions to the neurobiological mechanisms  
109 of schizophrenia.

110 Whereas in the striatum we found differences in ReFS, but not in mean-based GMV, significant group  
111 differences in regional mean and variance of grey matter volume (GMV) were apparent in non-striatal regions (**Fig.**

112 **1c and Table S3**), especially the hippocampus (HIP) and thalamus (THA), which is consistent with previous mean-  
113 based GMV studies (6, 13). We further revealed that subcortical regions with higher dopamine synthesis capacity  
114 (F-DOPA) demonstrated less differentiated mean-based GMV ( $\tau = -0.58$ ,  $P < 0.001$ , **Fig. 1d**) but higher F-FOPA-  
115 ReFS abnormalities ( $\tau = 0.48$ ,  $P < 0.001$ , **Fig. 1e**) between schizophrenic patients and controls. The results suggest  
116 that the reference-based spatial pattern was more closer to schizophrenia etiology.

117 Moreover, with a dataset consisting of healthy controls, schizophrenia patients, and unaffected siblings, we  
118 observed that the PET-ReFS revealed greater group differences than for mean-based GMV, especially in the  
119 striatum ( $t = 2.37$ ,  $P = 0.019$ , **Fig. 1f**) and the mean-based GMV of subcortical regions revealed no significant  
120 group differences (**Fig. 1f, Table S4**). For example, F-DOPA-ReFS in pPUT showed an apparent genetic  
121 susceptibility gradient for schizophrenia ( $F_{(2,72)} = 10.64$ ,  $P = 8.92E-05$ ) (**Fig. 1g and Table S4**), which is consistent  
122 with previous finding that elevated dopamine synthesis capacity (F-DOPA update) in the dorsal striatum of subjects  
123 at ultra-high risk for psychosis (14). These results suggest that the pattern-based representational analysis is  
124 sensitive in detecting the morphological disruptions associated with dopaminergic alterations in schizophrenia, and  
125 structural ReFS serve as an intermediate structural phenotype linking brain structure and genetic mechanisms  
126 underlying schizophrenia.

127 Furthermore, the PET-ReFS showed consistent group differences across all 13 datasets (**Table S5**), as shown  
128 in Figure 1 (pPUT: Cohen's  $d$  0.30~ 0.99; Overall:  $t = 10.62$ , Cohen's  $d = 0.49$ ,  $P = 8.17E-26$ ; **Fig1. h**). Subsequent  
129 sensitivity analyses showed that the effect of F-DOPA-ReFS in pPUT was robust to clinical subgroups (first  
130 episode and chronic, **Fig1. h**), disease duration (long and short duration groups), sex (male and female groups), and  
131 age (young and old groups) (**Table S6**), while the effect of GABAa-ReFS in pPUT was observed in the chronic  
132 patients, but not in the first-episodic subgroup (**Fig1. h and Table S6**).

133 In summary, these findings indicated that reference-based spatial pattern analysis exhibits high consistency  
134 and sensitivity, and it outperforms traditional univariate mean-based analysis in detecting fine-grained structural  
135 abnormalities within dopaminergic brain regions.

### 136 ***Structural abnormality of dorsal striatal ReFS with latent cognitive factor in schizophrenia***

137 Databases of brain activation maps provides a quantitative approach to infer plausible cognitive processes  
138 related to a spatial pattern, which might provide greater insight into the nature of the mental processes that are  
139 disrupted in the course of schizophrenia (15). We utilized meta-analytical decoding references from the *Neurosynth*  
140 dataset to transform individual-level spatial pattern of each subcortical region into a high-dimensional latent

141 cognitive factor (termed as Cog-ReFS, **Fig S8**) (16, 17). Again, after controlling for multiple comparisons with the  
142 Benjamini–Hochberg procedure (16 region\*539 cognitive factors), we found that the abnormalities of Cog-ReFS in  
143 schizophrenia patients were mainly located in dorsal striatal regions (63.4%, 1009/1591 significant Cog-ReFS),  
144 especially the posterior globus pallidus (pGP, 247 Cog-ReFS) and pPUT (274 Cog-ReFS) (**Fig. 2 a** and **Table S7**).

145 For instance, we observed significantly increased Cog-ReFS in pPUT with sensory-motor factors, such as "*eye*  
146 *movement*" and "*hand*", as well as social factors and decisions, such as "*theory of mind*" and "*appraisal*" in  
147 schizophrenia patients (**Fig. 2b**). Such an observation is in line with characteristic deficits or deteriorations in both  
148 motor and social factors of schizophrenia (18). Similarly, schizophrenia patients also showed a greater Cog-ReFS  
149 of motor-related factors (such as "*finger tapping*") but a lower Cog-ReFS for emotional and social functions such as  
150 "*familiarity*" and "*fearful face*" in pGP (**Fig. 2b**), where the "*finger tapping*" test is a commonly adopted measure  
151 of motor deficits in schizophrenia (19). In addition, for Cog-ReFS in the dorsal anterior thalamus (daTHA), the  
152 "*illusion*" term was the most prominent finding (**Fig. 2b**). Notably, delusions-related functions ("*biases*",  
153 "*appraisal*") are the hallmark positive symptoms of schizophrenia (20, 21).

154 Further, by investigating the correlations between the Cog-ReFS case/control differences and the third-party  
155 pattern similarity of cognitive factor maps and neurotransmitter maps (**Supplementary method and Fig S9**), we  
156 confirmed that the contribution of Cog-ReFS for schizophrenia could be partly explained by the neurotransmitters  
157 (**Fig. 2c, Table S8**). The above results altogether hence suggested that structural representational pattern could  
158 integrate cognitive factor and molecular neurotransmitter to delineate the neuropsychopathological mechanism of  
159 schizophrenia convergently.

160 We then investigated whether the high-dimensional Cog-ReFS in subcortical brain regions could predict the  
161 clinical characterisation of schizophrenia, as measured by the Positive and Negative Syndrome Scale (PANSS).  
162 Leveraging a modified linear predictive model (**Supplementary Methods and Fig S10**), we found that subcortical  
163 Cog-ReFS could significantly predict the summary symptom score and all three symptom subscales (Summary  
164 score:  $r = 0.10$ ,  $P = 8.42E-05$ ; Positive symptoms:  $r = 0.075$ ,  $P = 0.011$ ; Negative symptoms:  $r = 0.13$ ,  $P = 5.37E-$   
165  $05$ ; General symptoms:  $r = 0.12$ ,  $P = 1.47E-04$ , **Fig. 2d**). We also found that the predictive weight of positive and  
166 negative subscale show significantly lower similarity (**Fig. 2e, Table S9**), suggesting that the latent cognitive  
167 factors mapping could effectively characterise the different neurobiological configurations of positive and negative  
168 schizophrenia symptoms. In terms of the regional predictive weights, the dorsal striatal regions again show  
169 predominant contributions, especially the GP and PUT (**Fig. 2f, Table S9**). At last, we show that only in aGP and  
170 pPUT, the positive and negative predictors of schizophrenia symptoms were significantly associated with the Cog-

171 ReFS case/control differences (Table S7-c, **Fig. 2g and Fig S11, Table S9**). These results might indicate that the  
172 psychopathology of schizophrenia and the clinical symptoms of schizophrenia patients could share similar  
173 cognitive abnormality spectra centred at the dorsal striatum.

#### 174 ***Genetic links between structural ReFS and schizophrenia***

175 Despite high heritability of both schizophrenia and striatal mean-based volumes, they were reported not to  
176 share similar genetic architectures(22). Given the above higher clinical relevance of reference-based spatial pattern  
177 for SCZ than mean-based volume, we last investigated whether structural ReFS with higher information specificity  
178 might help to bridge the gap between structural brain genetics and risk for schizophrenia.

179 Utilised imaging-genetic data of 34,497 participants of British ancestry from UK Biobank, we found the mean  
180 heritability ( $h^2$ ) of brain Cog-ReFS (8624, 16 regions\* 539 cognitive factors) across the 16 subcortical regions as  
181 30.1% (7.7%~61.9%, all  $P < 0.001$ , **Table S10 and Fig S12**). While the above heritability levels of Cog-ReFS are  
182 comparable with previous brain structural findings (23, 24), they are largely unchanged after regressing the  
183 corresponding brain volume (mean  $h^2 = 28.6\%$ , Difference heritability = 1.5%; individual heritability changes vary  
184 from -1.1% for vaTHA to 4.39% for aGP) (**Table S11 and Fig S12**). Hence, the subcortical Cog-ReFS may help to  
185 capture the remaining genetic variance of the subcortical structure that was largely missed by using volumetric  
186 measurements alone.

187 We then used a high-definition likelihood method to estimate the genetic correlation between schizophrenia  
188 and subcortical Cog-ReFS (22, 25) (**Fig. 3a left**). After controlling for multiple comparisons, the Cog-ReFS of all  
189 16 subcortical regions had significant genetic correlations with schizophrenia ( $|R_g|$ : 0.022~0.153, 2676 out of 8624  
190 ReFS, Fig. 3b, **Fig. 3a right and Table S12**). Remarkably, using the Cog-ReFS of pPUT, we identified 116 risk  
191 Cog-terms ( $R_g$  0.037~0.089, mainly for sensorimotor and attentional factors) and 122 protective Cog-terms ( $R_g$  -  
192 0.118~-0.033, mainly for social and language factors) for schizophrenia (**Fig. 3b and Table S13**).

193 We also identified significant genetic correlations between the PET-ReFS of pPUT with schizophrenia, i.e.  
194 positive for the ReFS of D2 (dopamine D2), F-DOPA and DAT (dopamine transporter) and negative for the ReFS  
195 of SERT (serotonin transporter) and GABA<sub>A</sub> (**Fig. 3b and Table S14**). In contrast, the genetic correlation between  
196 volumetric pPUT and SCZ was not significant ( $R_g = -0.01$ ,  $P = 0.46$ ), consistent with previous studies (26) (**Fig. 3b**  
197 **and Table S15**). Further, also in pPUT, the magnitude of genetic correlations between Cog-ReFS and schizophrenia  
198 was significantly associated with the Cog-ReFS difference between schizophrenia patients and controls ( $r = 0.84$ ,  $P$   
199  $_{perm} = 0.01$ , Fig S14), hence reassuring the central role of dorsal striatum for the shared cognitive abnormalities of

200 the psychopathology of schizophrenia and the clinical symptoms of schizophrenia.

201 Finally, we investigated univariate genetic variants shared between schizophrenia and subcortical Cog-ReFS.  
202 By associating subcortical ReFS (8624, 539\*16) with 279 single nucleotide polymorphisms (SNPs) identified in a  
203 recent schizophrenia genome-wide association study (GWAS) (26), we found significant SNP-brain associations for  
204 172 out of 279 SNPs (70%) after correction for multiple testing (**Fig. 3c**), with four top SNPs represented 46% of  
205 all significant SNP-brain associations (**Fig. 3c** and **Table S16**). In contrast, the subcortical volumes only have  
206 significant associations with 37 out of 279 SNPs (13%, **Table S17**). The associations of the four top SNPs showed  
207 different regional distributions (**Fig. 3d**, **Table S18**). For instance, the T allele of rs13107325 had the greatest  
208 number of associations across all the 16 subcortical regions and was also one of the top risk genetic effects in the  
209 original schizophrenia GWAS (OR = 1.15, P = 2.99E-23) (26). The rs13107325 was associated with increased Cog-  
210 ReFS in pPUT for motor-related factors and "*illusion*" and also decreased Cog-ReFS in pPUT with "*feelings*",  
211 "*language*", and "*theory of mind*" (**Fig. 3e** and **Table S15**). The above results hence confirmed highly overlapped  
212 genetic substrates between schizophrenia and subcortical brain regions using our ReFS approach.

## 213 ***Discussion***

214 The present study demonstrated the crucial role of dopamine-based striatal representational feature score  
215 (ReFS) in schizophrenic psychopathology, and remarkably, the increased striatal dopamine-ReFS in schizophrenic  
216 patients could be consistently reproduced across all 13 tested independent datasets. In contrast, previous large-  
217 sample structural studies rarely found consistent mean/variance-based volumetric alternations of striatum in chronic  
218 or antipsychotic-free schizophrenia patients (27, 28). Such a discrepancy could be explained by our observations  
219 that brain regions with higher dopamine density tend to have diminished case-control brain mean-based volume  
220 difference while, instead, showing increased differences in the corresponding dopamine-ReFS. Notably, this effect  
221 of increased striatal dopamine-ReFS was also evident in the antipsychotic-free schizophrenia subgroup and the  
222 first-degree healthy relatives of schizophrenia patients. Therefore, the increased striatal dopamine-ReFS were most  
223 unlikely the results of confounding effects from antipsychotic medications and could serve as endophenotypic  
224 biomarkers for the vulnerability of dopaminergic dysfunction in schizophrenia.

225 Further, with high-dimensional latent cognitive factors, we found that the structural Cog-ReFS abnormalities  
226 in schizophrenia were also primarily located in the striatum, particularly the dorsal part (i.e. the globus pallidus, GP  
227 and the putamen, PUT), which corroborates a recent proposition asserting the central role of the dorsal striatum in  
228 the pathophysiology of schizophrenia (29). The dorsal striatum has been proposed as an integrative hub that  
229 regulates information transactions between limbic and motor regions (30), most notably through the dopaminergic



230 projections from SNc. Our results indicated that Cog-ReFS abnormalities of the dorsal striatum in schizophrenia  
231 could influence multiple latent cognitive domains (i.e., motor-related, decision-making, and social-emotional  
232 functions). Besides, in the predictive model for the three schizophrenia symptom subscales (i.e., positive, negative  
233 and general subscales from PANSS) using all subcortical Cog-ReFS, the dorsal striatum was the primary  
234 contributor. These findings supported that dorsal striatum dysfunction was not merely associated with motor  
235 deficits in schizophrenia but may also contribute to other psychopathologies (such as emotionlessness and delusion)  
236 in schizophrenia. Therefore, the dorsal striatal dopamine level could be a promising treatment target for  
237 schizophrenia (9, 31). In a recent clinical trial, a highly selective M4 positive allosteric modulator, i.e. responsible  
238 for dopamine release in the dorsal striatum, has demonstrated a favourable safety profile in schizophrenia treatment  
239 (32).

240 Previous studies have consistently found a surprisingly low genetic correlation between schizophrenia and  
241 brain subcortical mean-based volume (22), which, as suggested by a recent finding (33), is likely because  
242 subcortical mean-based volume and schizophrenia share plenty of common genetic variants but with heterogeneous  
243 effects directions. In the present study, ReFS of multiple subcortical regions demonstrated significant genetic  
244 correlations with schizophrenia, indicating that ReFS could help to capture a more homogenous genetic construct of  
245 brain structure shared with schizophrenia (34). In terms of common genetic variants, we demonstrated that the same  
246 SCZ risk alleles were simultaneously associated with increased positive-symptom Cog-ReFS (i.e. motor and  
247 hallucination) and decreased negative-symptom Cog-ReFS (i.e. emotion, social and language) (Figure 3E), and  
248 both groups of Cog-ReFS were also associated with schizophrenia diagnoses (Figure 2B). Hence, this latent  
249 representation-based brain pattern (i.e. the ReFS) could also provide valuable insights into the genetic construction  
250 of neural mechanisms underlying schizophrenia.

251

## 252 **Acknowledgements**

253 **Author contributions:** Conceptualization: C.X., T.J.T., F.F.J.; Methodology: C.X., T.J.T.; Formal analysis: C.X.;  
254 Writing: original draft: C.X., T.J.T.; Writing-review and editing: C.X., T.J.T, O.H., G.S., T.R. **Competing interests:**  
255 The authors declare no competing interests. .

256

## 257 **SUPPLEMENTARY MATERIALS**

### 258 **Materials and Methods**


259 **Figs. S1 to S14**

260 **Tables S1 to S20**

261 **ACKNOWLEDGMENTS**

262 COBRE (The Center for Biomedical Research Excellence in Brain Function and Mental Illness) has published  
263 structural and functional MRI data obtained from schizophrenia patients and normal subjects. MCICShare  
264 comprised structural and resting-state functional MRI data, which was collected and shared by the Mind Research  
265 Network and the University of New Mexico funded by a National Institute of Health Center of Biomedical  
266 Research Excellence (COBRE) grant 1P20RR021938-01A2. Research using Human Connectome Project for Early  
267 Psychosis (HCP-EP) data reported in this publication was supported by the National Institute of Mental Health of  
268 the National Institutes of Health under Award Number U01MH109977. The HCP-EP 1.1 Release data used in this  
269 report came from DOI: 10.15154/1522899. This work received support from the following sources: the National  
270 Natural Science Foundation of China (T2122005 [to TJ], 82150710554 [to GS], KRH2306051 [CX] and 81801773  
271 [to TJ]), China Postdoctoral Science Foundation (no. BX20230075 and 2023M740659 to CX). MOE Frontiers  
272 Center for Brain Science [to CX], National Key R and D Program of China (2023ZY1068 [to TJ],  
273 2019YFA0709501 [to TJ], 2021YFC2501402 [to TJ], 2019YFA0709502 [to JF], 2018YFC1312900 [to TJ] and  
274 2018YFC1312904 [to JF]), the Shanghai Pujiang Project (18PJ1400900 [to TJ]), Guangdong Key Research and  
275 Development Project (No. 2018B030335001 [to JF]), the European Union-funded FP6 Integrated Project IMAGEN  
276 (Reinforcement-related behavior in normal brain function and psychopathology) (LSHM-CT- 2007-037286 [to  
277 GS]), the Horizon 2020-funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of  
278 reinforcement-related disorders) (695313 [to GS]), the 111 Project (B18015 [to JF]), the key project of Shanghai  
279 Science and Technology (16JC1420402 [to JF]), Shanghai Municipal Science and Technology Major Project (no.  
280 2018SHZDZX01 [to JF]), ZJ Lab [to JF], Shanghai Center for Brain Science and Brain-Inspired Technology [to JF],  
281 ERANID (Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways)  
282 (PR-ST-0416-10004, [to GS]), Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539, [to GS]), the  
283 Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalising Disorders and Addictions)  
284 (MR/N000390/1 [to GS]), the National Institute of Health (NIH) (R01DA049238, A decentralised macro and micro  
285 gene-by-environment interaction analysis of substance use behavior and its brain biomarkers [to GS]), the National  
286 Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation  
287 Trust and King's College London, the Bundesministerium für Bildung und Forschung (BMBF grants 01GS08152;  
288 01EV0711 [to GS]; the European Union and UKRI funded project environmental (grants 101057429 [to GS]).


289 Forschungsnetz AERIAL 01EE1406A, 01EE1406B [to GS]), Forschungsnetz IMAC-Mind 01GL1745B [to GS]),  
290 the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1, [to GS]).  
291



292

293 **Fig 1. The structural pattern-based representation feature analysis of striatum in schizophrenia.** **a. Concept**  
 294 **of pattern-based** representation feature analysis. In regions with high spatial heterogeneity, univariate analysis  
 295 with mean/variance-based grey matter volume (GMV) failed to find significant group difference between  
 296 schizophrenia patients (SCZ) and healthy controls (HC). Spatial organization of functional references provide an  
 297 priori knowledge to decompose the spatial pattern of GMV into different latent representation dimensions, which  
 298 was termed as representational feature score (ReFS). The pattern-based ReFS help to detect the subtle spatial  
 299 distribution alternations of brain structure. **b.** The reliability, reproducibility and sensitivity analysis results of the  
 300 ReFS and mean-based volume. For each region, we used nine different neurotransmitter maps as pattern reference  
 301 to estimate the pattern-based ReFS, such as FDOP-ReFS, D1-ReFS etc. With the F-DOPA as an example, the  
 302 reliability of brain ReFS was estimated as the spatial correlation between the F-DOPA maps from two public  
 303 available third-party datasets (Donders dataset and JuSpace). The reproducibility of brain ReFS and mean-based  
 304 volume was estimated as the intraclass correlation coefficient (ICC) with two repeated scanning datasets  
 305 (Myconnectome dataset, 1 participant was scanned 21 times; SIMON dataset, 1 participant was scanned 46 times).  
 306 The sensitivity of brain ReFS and mean-based volume was estimated as the accuracy in the brain fingerprint  
 307 analysis with a participant travelling dataset (SRPBS, 9 participants were scanned at 12 different sites). **c.** For each  
 308 subcortical region, there are complex nuanced group difference of spatial pattern between schizophrenia patients


309 and healthy controls. **d.** The group difference between schizophrenia and healthy control groups with univariate-  
310 based measurements of mean and variance and pattern-based ReFS, which was estimated with nine group-level  
311 neurotransmitter maps. **e.** In subcortex, the group difference of schizophrenia with mean-based volume was  
312 negatively associated with the group-level dopamine synthesis capacity (F-DOPA). **f.** In subcortex, the group  
313 difference of schizophrenia with F-DOPA-ReFS positively correlated with group-level dopamine synthesis capacity  
314 (F-DOPA). **g.** After multiple corrections with Benjamin–Hochberg procedure, subcortical region with mean-based  
315 volume did not show significant group difference between schizophrenia patients, unaffected siblings, and healthy  
316 controls; in contrast, the group difference with multiple PET-ReFS of striatum reached significant level, including  
317 F-DOPA-ReFS of pPUI, D2-ReFS of pPUT, MU-ReFS of pGP. In subcortex, the group difference with PET-ReFS  
318 exhibit significant higher level than with mean-based volume. The significance level was set as the corresponding  
319 multiple correction in 16 regional mean-based volumes and 144 (16 regions \* 9 neurotransmitters) pattern-based  
320 subcortical PET-ReFS. The upper and lower bars represent the  $Q3 + 1.5 \times IQR$  and  $Q1 - 1.5 \times IQR$ , respectively. The  
321 upper and lower edges of a box represent the Q3 and Q1, and the central line represents the median. Outliers are  
322 illustrated as bold dots. **h.** F-DOPA-ReFS of pPUT demonstrates a significant genetic risk gradient from healthy  
323 controls, through unaffected siblings, to schizophrenia patients. **i.** Forest plot showing the effect sizes for the F-  
324 DOPA-ReFS and GABA-ReFS of pPUT between schizophrenia patients and healthy controls. Meta-analysis  
325 showed there was significantly higher F-DOPA-ReFS for pPUT (cohen's  $d=0.52$  (95% CI = [0.41, 0.63]);  $P <$   
326  $0.0001$ ), whilst it was significantly lower for GABA-ReFS for o=pPUT in schizophrenia relative to controls  
327 (cohen's  $d=-0.45$  (95% CI= [-0.62 -0.28]);  $P < 0.0001$ ). Abbreviation: *SCZ*, schizophrenia patient; *HC*, healthy  
328 control; *ICC*, intraclass correlation coefficient; *F-DOP*, Fluorodopa; *FES*, First episode schizophrenia patient;  
329 *Chronic*: Chronic schizophrenia patient; Early Psy. Early psychosis patient. Sig. level, Significant level after  
330 multiple correction; \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . Q1, first quartile; Q3, third quartile; IQR, interquartile  
331 range; SIMON, The Single Individual volunteer for Multiple Observations across Networks dataset; SRPBS,  
332 Japanese Strategic Research Program for the Promotion of Brain Science. aHIP, anterior hippocampus; pHIP,  
333 posterior hippocampus; lAMY, lateral amygdala; mAMY, medial amygdala; vpTHA, ventral posterior thalamus;  
334 vaTHA, ventral anterior thalamus; dpTHA, dorsal posterior thalamus; daTHA, dorsal anterior thalamus; coreNAC,  
335 core nucleus accumbens; shellNAC, shell nucleus accumbens; aGP; pGP; aPUT; pPUT; aCAU; pCAU; FDOP;  
336 GABA; D1, D2, SERT, MU, NAT; DAT;  
337



338

339 **Fig 2. Striatal ReFS with multidimensional latent cognitive factors in schizophrenia patients.** a. Manhattan  
 340 plot illustrates significant group differences between schizophrenia and healthy controls in Cog-ReFS of subcortical  
 341 regions, particularly in pGP and pPUT. b. The group difference of Cog-ReFS in pPUT, pGP and daTHA. c. In these  
 342 regions, group differences of Cog-ReFS were notably modulated by neurotransmitters. d. High dimensional Cog-  
 343 ReFS in subcortical regions could significantly predict the schizophrenic symptom subscales. e. The similarity  
 344 between predictive weights for different schizophrenia symptom subscales. f. The regional contribution of  
 345 subcortical Cog-ReFS in the predictive models of schizophrenia symptoms. g. The similarity between the summary  
 346 symptom's predictive contributors and case/control difference for all the Cog-ReFS in each subcortical region.  
 347

348



349

350 **Fig 3. The shared genetic basis between brain Cog-ReFS and schizophrenia**

351 **a.** The genetic correlations were calculated between brain ReFS (i.e. PET-ReFS and Cog-ReFS) of subcortical regions (GWAS using UKB) and the

352 summary statistics from a recent schizophrenia GWAS (Left). The counts of significant findings are shown on the

353 Right. **b.** In pPUT, ReFS with 125 latent cognitive factors and three neurotransmitters (D2, F-DOPA, DAT) had

354 positive significant genetic correlations with schizophrenia, and 138 latent cognitive factors and two

355 neurotransmitters (SERT1 and GABA) had negative genetic correlations. The volume of pPUT was not

356 significantly associated with schizophrenia. **c.** Among the 279 single nucleotide polymorphisms (SNPs) from a

357 recent schizophrenia GWAS, 70% of SNPs (172) have significant correlations with the subcortical ReFS after false

358 discovery rate (FDR) correction and only 13% SNPs with subcortical mean-based volume. Four SNPs, i.e.

359 rs13107325, rs8084351, rs9398171, and rs7604885, predominated the SNP-brain ReFS associations (46%). **d.** The

360 SNP-brain ReFS associations of the four most representative SNPs showed different regional distributions. **e.** SNP

361 rs13107325 showed negative associations with the Cog-ReFS in pPUT for social emotion and language terms and

362 positive associations for motor and illusion terms. Rg, the genetic correlation; ReFS, representational feature score;

363 GWAS, genome-wide association study; UKB, UK biobank

364

365

366

367 **Reference**

368

- 369 1. S. J. Kaar, S. Natesan, R. McCutcheon, O. D. Howes, Antipsychotics: Mechanisms underlying clinical response  
370 and side-effects and novel treatment approaches based on pathophysiology. *Neuropharmacology* **172**, 107704  
371 (2020).
- 372 2. M. C. Lobo, T. S. Whitehurst, S. J. Kaar, O. D. Howes, New and emerging treatments for schizophrenia: a  
373 narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.  
374 *Neurosci Biobehav Rev* **132**, 324-361 (2022).
- 375 3. O. D. Howes, S. Kapur, The dopamine hypothesis of schizophrenia: version III--the final common pathway.  
376 *Schizophr Bull* **35**, 549-562 (2009).
- 377 4. S. Jauhar *et al.*, A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission  
378 Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. *JAMA Psychiatry* **74**, 1206-1213 (2017).
- 379 5. O. D. Howes, C. Cummings, G. E. Chapman, E. Shatalina, Neuroimaging in schizophrenia: an overview of  
380 findings and their implications for synaptic changes. *Neuropsychopharmacology* **48**, 151-167 (2023).
- 381 6. T. G. van Erp *et al.*, Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540  
382 healthy controls via the ENIGMA consortium. *Mol Psychiatry* **21**, 547-553 (2016).
- 383 7. S. V. Haijma *et al.*, Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. *Schizophr Bull* **39**,  
384 1129-1138 (2013).
- 385 8. S. P. Brugger, O. D. Howes, Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A  
386 Meta-analysis. *JAMA Psychiatry* **74**, 1104-1111 (2017).
- 387 9. R. McCutcheon, K. Beck, S. Jauhar, O. D. Howes, Defining the Locus of Dopaminergic Dysfunction in  
388 Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. *Schizophr Bull* **44**, 1301-1311 (2018).
- 389 10. N. Chuhma, S. Mingote, A. Kalmbach, L. Yetnikoff, S. Rayport, Heterogeneity in Dopamine Neuron Synaptic  
390 Actions Across the Striatum and Its Relevance for Schizophrenia. *Biol Psychiatry* **81**, 43-51 (2017).
- 391 11. K. M. Gothard, Multidimensional processing in the amygdala. *Nat Rev Neurosci* **21**, 565-575 (2020).
- 392 12. N. Kriegeskorte, R. A. Kievit, Representational geometry: integrating cognition, computation, and the brain.  
393 *Trends Cogn Sci* **17**, 401-412 (2013).
- 394 13. D. Alnaes *et al.*, Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk. *JAMA*  
395 *Psychiatry*, (2019).
- 396 14. A. Egerton *et al.*, Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings  
397 in a second cohort. *Biol Psychiatry* **74**, 106-112 (2013).
- 398 15. S. Lariviere *et al.*, BrainStat: A toolbox for brain-wide statistics and multimodal feature associations.  
399 *Neuroimage* **266**, 119807 (2023).
- 400 16. T. Yarkoni, R. A. Poldrack, T. E. Nichols, D. C. Van Essen, T. D. Wager, Large-scale automated synthesis of  
401 human functional neuroimaging data. *Nat Methods* **8**, 665-670 (2011).
- 402 17. V. R. Karolis, M. Corbetta, M. Thiebaut de Schotten, The architecture of functional lateralisation and its  
403 relationship to callosal connectivity in the human brain. *Nat Commun* **10**, 1417 (2019).
- 404 18. R. A. McCutcheon, T. Reis Marques, O. D. Howes, Schizophrenia-An Overview. *JAMA Psychiatry*, 1-10 (2019).
- 405 19. T. Suto, M. Fukuda, M. Ito, T. Uehara, M. Mikuni, Multichannel near-infrared spectroscopy in depression and  
406 schizophrenia: cognitive brain activation study. *Biological psychiatry* **55**, 501-511 (2004).
- 407 20. D. A. Silbersweig *et al.*, A functional neuroanatomy of hallucinations in schizophrenia. *Nature* **378**, 176-179  
408 (1995).
- 409 21. B. F. McLean, J. K. Mattiske, R. P. Balzan, Association of the Jumping to Conclusions and Evidence Integration  
410 Biases With Delusions in Psychosis: A Detailed Meta-analysis. *Schizophr Bull* **43**, 344-354 (2017).
- 411 22. B. Franke *et al.*, Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of



- 412 concept. *Nat Neurosci* **19**, 420-431 (2016).
- 413 23. S. M. Smith *et al.*, An expanded set of genome-wide association studies of brain imaging phenotypes in UK  
414 Biobank. *Nat Neurosci* **24**, 737-745 (2021).
- 415 24. B. Zhao *et al.*, Genome-wide association analysis of 19,629 individuals identifies variants influencing regional  
416 brain volumes and refines their genetic co-architecture with cognitive and mental health traits. *Nat Genet* **51**,  
417 1637-1644 (2019).
- 418 25. Z. Ning, Y. Pawitan, X. Shen, High-definition likelihood inference of genetic correlations across human  
419 complex traits. *Nat Genet* **52**, 859-864 (2020).
- 420 26. V. Trubetsky *et al.*, Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*,  
421 (2022).
- 422 27. X. Gao *et al.*, Association between structural and functional brain alterations in drug-free patients with  
423 schizophrenia: a multimodal meta-analysis. *Journal of Psychiatry and Neuroscience* **43**, 131-142 (2018).
- 424 28. S. S. Kuo, M. F. Pogue-Geile, Variation in fourteen brain structure volumes in schizophrenia: A comprehensive  
425 meta-analysis of 246 studies. *Neurosci Biobehav Rev* **98**, 85-94 (2019).
- 426 29. R. A. McCutcheon, A. Abi-Dargham, O. D. Howes, Schizophrenia, Dopamine and the Striatum: From Biology  
427 to Symptoms. *Trends Neurosci* **42**, 205-220 (2019).
- 428 30. B. J. Hunnicutt *et al.*, A comprehensive excitatory input map of the striatum reveals novel functional  
429 organization. *elife* **5**, e19103 (2016).
- 430 31. S. E. Yohn *et al.*, Activation of the mGlu(1) metabotropic glutamate receptor has antipsychotic-like effects and  
431 is required for efficacy of M(4) muscarinic receptor allosteric modulators. *Mol Psychiatry* **25**, 2786-2799 (2020).
- 432 32. J. H. Krystal *et al.*, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the  
433 treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. *Lancet*  
434 (*London, England*) **400**, 2210-2220 (2022).
- 435 33. W. Cheng *et al.*, Shared genetic architecture between schizophrenia and subcortical brain volumes implicates  
436 early neurodevelopmental processes and brain development in childhood. *Mol Psychiatry*, (2022).
- 437 34. V. Anttila *et al.*, Analysis of shared heritability in common disorders of the brain. *Science* **360**, eaap8757 (2018).
- 438